StockNews.com upgraded shares of Dynavax Technologies (NASDAQ:DVAX – Free Report) from a hold rating to a buy rating in a report published on Monday morning.
Other equities research analysts also recently issued research reports about the company. HC Wainwright restated a buy rating and set a $29.00 price objective on shares of Dynavax Technologies in a report on Thursday, May 9th. The Goldman Sachs Group began coverage on shares of Dynavax Technologies in a report on Thursday, February 1st. They set a neutral rating and a $20.00 price objective on the stock. Finally, William Blair reiterated an outperform rating on shares of Dynavax Technologies in a report on Friday, February 23rd. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of Moderate Buy and an average price target of $25.33.
View Our Latest Stock Report on Dynavax Technologies
Dynavax Technologies Stock Performance
Insider Activity at Dynavax Technologies
In other news, CAO Justin Burgess sold 20,526 shares of the company’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $12.78, for a total value of $262,322.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 2.98% of the stock is currently owned by insiders.
Hedge Funds Weigh In On Dynavax Technologies
A number of hedge funds and other institutional investors have recently modified their holdings of DVAX. Charles Schwab Investment Management Inc. increased its position in shares of Dynavax Technologies by 9.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,081,789 shares of the biopharmaceutical company’s stock valued at $15,978,000 after acquiring an additional 95,690 shares during the last quarter. Bank of New York Mellon Corp grew its stake in Dynavax Technologies by 20.5% in the 3rd quarter. Bank of New York Mellon Corp now owns 1,359,729 shares of the biopharmaceutical company’s stock valued at $20,083,000 after purchasing an additional 231,731 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Dynavax Technologies by 8.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 80,820 shares of the biopharmaceutical company’s stock valued at $1,194,000 after purchasing an additional 6,339 shares during the last quarter. Teacher Retirement System of Texas raised its stake in shares of Dynavax Technologies by 4.7% during the 3rd quarter. Teacher Retirement System of Texas now owns 36,484 shares of the biopharmaceutical company’s stock worth $539,000 after purchasing an additional 1,652 shares during the period. Finally, Vanguard Group Inc. boosted its holdings in shares of Dynavax Technologies by 3.1% in the 3rd quarter. Vanguard Group Inc. now owns 9,146,891 shares of the biopharmaceutical company’s stock worth $135,100,000 after buying an additional 270,730 shares during the last quarter. Hedge funds and other institutional investors own 96.96% of the company’s stock.
Dynavax Technologies Company Profile
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.
Featured Stories
- Five stocks we like better than Dynavax Technologies
- What is the Australian Securities Exchange (ASX)
- TJX Companies Can Hit New Highs; Double-Digit Upside to Follow
- 3 Best Fintech Stocks for a Portfolio Boost
- A Hidden Gem Retailer With 20% Upside
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Zoom Stock’s Earnings Volatility Picked Up a Lot of Buyers
Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.